{
  "docId": "019de075-4071-7657-953a-43c246cbe714",
  "docSlug": "684835678957e07d55af9fc01c6da54e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 44 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 44,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a two-column layout to contrast near-term growth drivers with mid-term pipeline developments.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-4071-7657-953a-43c246cbe714/16",
  "deckHref": "/decks/019de075-4071-7657-953a-43c246cbe714",
  "deckJsonHref": "/decks/019de075-4071-7657-953a-43c246cbe714.json",
  "deckAnchorHref": "/decks/019de075-4071-7657-953a-43c246cbe714#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.95,
        "x": 0.03,
        "y": 0.94
      },
      "kind": "disclaimer",
      "text": "LCM = lifecycle management; IO = immuno-oncology; HCC = hepatocellular carcinoma; OS = overall survival; ESMO = European Society of Medical Oncology; GI = gastrointestinal; GEJ = gastroesophageal junction; BTC = biliary tract cancer; SoC = standard of care; JP = Japan; NSCLC = non-small cell lung cancer; HLR = high-level results; EFS = event-free survival; CTx = chemotherapy; FLOT = fluorouracil, leucovorin, oxaliplatin and docetaxel; cCRT = concurrent chemoradiotherapy; PFS = progression free survival; TACE = transarterial chemoembolisation.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "051d8805-dce3-4933-bcd9-991076e5b46b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "HIMALAYA (unresectable HCC), TOPAZ-1 (1L BTC), POSEIDON (1L NSCLC) launch details",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "aa26a510-9972-4fa3-9c59-56e7650a82e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.4,
        "x": 0.55,
        "y": 0.35
      },
      "kind": "list",
      "text": "AEGEAN, DUO-O, DUO-E, MATTERHORN, PACIFIC-2, EMERALD-1 pipeline status",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c981a77e-d3b2-494d-af24-89d9dd5c3fdc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.03,
        "y": 0.8
      },
      "kind": "subtitle",
      "text": "New launch momentum (POSEIDON, HIMALAYA, TOPAZ) builds on top of sustained leadership in PACIFIC, CASPIAN",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5f1f6b8-2d56-4e8c-9e6f-ceef69a1cc59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.03,
        "y": 0.13
      },
      "kind": "title",
      "text": "Strong launch uptake, robust LCM pipeline supporting continued IO leadership",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1fb71a77-1d4f-4e5d-811f-df6f0793f7eb",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.55,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Oncology – key Imfinzi opportunities in focus",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ba20ece4-47d6-4e80-85cb-b72d51f234c8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 9,
      "beatId": "1f13dd9d-adda-48c7-ad5c-4e44ba8f57d7",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "The presentation showcases AstraZeneca's financial results, R&D highlights, and sustainability initiatives, providing a sense of satisfaction",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 22,
      "from": 5,
      "name": "Pattern Hunter",
      "slug": "02-pattern-hunter",
      "bestFor": "Time-pressed audiences, building consensus, when data is strong",
      "matchId": "8f711e18-1f16-4fa6-b2d7-b917fe429d2f",
      "evidence": "The presentation highlights multiple examples of AstraZeneca's growth and innovation across different disease areas",
      "position": 0,
      "objective": "To identify patterns and trends in AstraZeneca's growth and innovation",
      "structure": "Evidence A -> Evidence B -> Evidence C -> Pattern/Conclusion",
      "confidence": 0.6,
      "description": "Group multiple pieces of evidence that together point to a pattern or conclusion"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}